|
Rheumatoid Arthritis Therapy: Biologic Therapy
Session Type: ACR Concurrent Abstract Sessions
Sunday, October 18, 2009: 4:30 PM-6:00 PM
103 A (Pennsylvania Convention Center)
Organizers: |
Eric M. Ruderman, MD, Northwestern University Feinberg School of Medicine
and
Daniel Aletaha, MD, Medical University of Vienna
|
Moderators: |
Vibeke Strand, M.D., Stanford University
and
Richard W. Martin, M.D., MA, Michigan State University College of Human Medicine
|
Papers:
4:30 PM
Smoking Is Associated with Non-Response to Methotrexate and to Anti-TNF Treatment in Patients with Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir, MD, PhD, Karolinska University Hospital;
Sara Wedrén, MD, PhD, Karolinska Institutet;
Maria Seddighzadeh, PhD, Karolinska Institutet;
Johan Askling, MD, PhD, Karolinska University Hospital;
Leonid Padyukov, MD, PhD, Karolinska Institutet;
Lars Alfredsson, PhD, Karolinska Institutet;
Lars Klareskog, MD, PhD, Karolinska University Hospital
4:45 PM
Rituximab in Combination with Methotrexate (MTX) Significantly Inhibits Joint Damage and Improves Clinical Outcomes in Patients with Early Active RA Who Are Naïve to MTX: A Randomized Active Comparator Placebo-Controlled Trial (IMAGE)
Paul P. Tak, MD, PhD, Academic Medical Center/ University of Amsterdam;
William F. C. Rigby, MD, Dartmouth Hitchcock Medical Center;
Andrea Rubbert-Roth, M, University of Cologne;
Charles G. Peterfy, MD, PhD, Synarc Inc.;
Ronald F. van Vollenhoven, MD, PhD, The Karolinska Institute;
William Stohl, MD, PhD, Univ Southern California;
Eva Hessey, BSc, MSc, Roche Products Ltd;
Annie C. Chen, MD, MPH, Genentech, Inc;
Helen Tyrrell, BSc, Roche Products Ltd;
Tim M. Shaw, Roche Products Ltd
5:15 PM
Disease Remission Is Achieved within Two Years in Over Half of Methotrexate Naive Patients with Early Erosive Rheumatoid Arthritis (RA) Treated with Abatacept Plus MTX: Results From the AGREE Trial
R. Westhovens, MD, PhD, UZ Gasthuisberg, KU Leuven;
M. Robles, M.D., Centrol Medico Toluca;
S. Nayiager, St Augustine's Hospital;
J. Wollenhaupt, MD, Klinikum Eilbek;
P. Durez, M, PhD, Univ Catholique de Louvain;
J. Gómez-Reino, M, PhD, Hospital Clinico Univ De Santiago;
W. Grassi, M, PhD, Univ Politecnica delle Marche;
B. Haraoui, MD, Institut de Rhumatolgie de Montreal;
W. Shergy, MD, Univ of Alabama;
SH Park, MD, PhD, Kangnam St Mary's Hosp;
H. Genant, MD, University of California;
C. Peterfy, MD, PhD, SYNARC, Inc;
J.-C. Becker, MD, Bristol-Myers Squibb;
A. Covucci, Bristol-Myers Squibb;
R. Helfrick, Bristol-Myers Squibb;
J. Bathon, MD, Johns Hopkins Univ Sch of Med
5:30 PM
Reduced Radiographic Progression in Patients with Early Rheumatoid Arthritis (RA) Treated with Abatacept + Methotrexate Compared to Methotrexate Alone: 24 Month Outcomes
J. Bathon, MD, Johns Hopkins Univ Sch of Med;
H. Genant, MD, University of California;
S. Nayiager, St Augustine's Hospital;
J. Wollenhaupt, MD, Klinikum Eilbek;
P. Durez, M, PhD, Univ Catholique de Louvain;
J. Gómez-Reino, M, PhD, Hospital Clinico Univ De Santiago;
W. Grassi, M, PhD, Univ Politecnica delle Marche;
B. Haraoui, MD, Institut de Rhumatolgie de Montreal;
W. Shergy, MD, Univ of Alabama;
SH Park, MD, PhD, Kangnam St Mary's Hosp;
M. Robles, M, Centrol Medico Toluca;
C. Peterfy, MD, PhD, SYNARC, Inc;
J.-C. Becker, MD, Bristol-Myers Squibb;
A. Covucci, Bristol-Myers Squibb;
R. Helfrick, Bristol-Myers Squibb;
R. Westhovens, MD, PhD, UZ Gasthuisberg, KU Leuven
5:45 PM
Golimumab and Radiographic Progression in Rheumatoid Arthritis: Results of GO-BEFORE and GO-FORWARD Studies
P. Emery, FRCP, MA, MD, Univ Leeds;
R. Fleischmann, MD, U of Texas Southwest Med Center;
Désirée M.F.M. van der Heijde, MD, PhD, Leiden University Medical Center;
Edward C. Keystone, M.D., FRCP, (C), Professor of Medicine/University of Toronto;
M. C. Genovese, MD, Stanford University;
P. G. Conaghan, M.D., PhD, U of Leeds;
E. C. Hsia, MD, Centocor R&D, Inc/U of Penn School of Med;
W. Xu, PhD, Centocor R&D, Inc;
A. Baratelle, BSRT, Centocor R&D;
A. Beutler, MD, Centocor R&D, Inc;
M. U. Rahman, MD, PhD, Centocor R&D, Inc/U of Penn School of Med
|